文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

澳大利亚男男性行为者无症状淋病筛查与头孢曲松消耗模式关联的回顾性观察研究

Asymptomatic Screening for Neisseria gonorrhoeae Among Gay and Bisexual Men Attending Public Sexual Health Services in Australia and Associations With Patterns of Ceftriaxone Consumption: A Retrospective Observational Study.
PubMed 文献 · J Infect Dis · 2026-01-01

该回顾性队列研究纳入2016至2023年澳大利亚16家公共性健康服务机构中接受淋病筛查的65 261名男男性行为者,共133 846人年。总头孢曲松处方率从2.92 DDD/100人年升至5.25,其中筛查相关处方从0.91升至2.96(P<.001),非筛查相关保持稳定(P=.570)。与每年1次筛查相比,≥4次筛查者的筛查相关头孢曲松处方率更高(aIRR 5.47,95%CI 5.16-5.79)。

要点

  • 筛查相关头孢曲松消耗显著上升,非筛查相关保持稳定。
  • 高频筛查(≥4次/年)与筛查相关头孢曲松处方率升高独立相关。
  • 需权衡高频筛查的收益与抗菌药物消耗及耐药风险。

核心结论

  • 男男性行为者头孢曲松消耗上升主要由筛查相关处方增加驱动,而非非筛查相关治疗。
  • 高频筛查与筛查相关头孢曲松处方率升高存在关联。

研究设计与样本

  • 回顾性队列研究,纳入2016至2023年澳大利亚16家公共性健康服务机构中接受淋病筛查的65 261名男男性行为者,共133 846人年。
  • 将淋病检测和头孢曲松处方分类为筛查相关(无症状筛查)或非筛查相关(接触者检测/治疗、有症状检测或经验性治疗)。
  • 采用多因素Poisson回归分析年度无症状筛查频率与头孢曲松消耗的关联,调整年龄、年份、暴露前预防、HIV状态、注射吸毒及梅毒和衣原体诊断。

主要发现

  • 总头孢曲松处方率从2016年的2.92 DDD/100人年升至2023年的5.25 DDD/100人年。
  • 筛查相关头孢曲松从0.91升至2.96 DDD/100人年(P<.001),非筛查相关保持稳定(P=.570)。
  • 与每年1次筛查相比,每年≥4次筛查与筛查相关头孢曲松处方率升高相关(调整后发病率比5.47,95%CI 5.16-5.79)。

临床怎么用

  • 临床中应关注高频无症状淋病筛查对头孢曲松消耗的影响,结合个体风险权衡筛查频率。
  • 在制定男男性行为者淋病筛查策略时,需考虑抗菌药物管理及耐药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neisseria gonorrhoeae is a significant public health concern due to rising antimicrobial resistance. Current strategies for N gonorrhoeae among gay and bisexual men (GBM) include 3-month screening; however, high-frequency screening may increase ceftriaxone consumption, potentially contributing to antimicrobial resistance. METHODS: We conducted a retrospective cohort study of GBM screened for N gonorrhoeae at 16 Australian public sexual health services between 2016 and 2023. We classified N gonorrhoeae tests and ceftriaxone prescriptions as screening-related (asymptomatic screening) or nonscreening-related (testing/treatment of contacts, symptomatic testing, or empirical treatment). We explored trends in annual ceftriaxone prescription rates and used multivariable Poisson regression to examine the association between individuals' annual asymptomatic screening frequency and ceftriaxone consumption, adjusted for age, year, pre-exposure prophylaxis, HIV status, injecting drug use, and syphilis and chlamydia diagnoses. RESULTS: In total, 65 261 GBM contributed 133 846 person-years. From 2016 to 2023, the total ceftriaxone prescription rate rose from 2.92 defined daily doses per 100 person-years at risk to 5.25: screening-related ceftriaxone increased from 0.91 to 2.96 (P < .001) while nonscreening-related ceftriaxone remained stable (P = .570). When compared with having 1 screening test per year, having ≥4 tests was associated with a higher rate of screening-related ceftriaxone prescriptions (adjusted incident rate ratio, 5.47; 95% CI, 5.16-5.79). CONCLUSIONS: Ceftriaxone consumption rose among GBM, largely driven by increased screening rather than nonscreening-related treatment. Our findings highlight the association between high-frequency screening and antibiotic consumption, providing real-world data to guide discussions on the benefits and risks of screening.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wong A, Aung HL, Varma R, et al. Asymptomatic Screening for Neisseria gonorrhoeae Among Gay and Bisexual Men Attending Public Sexual Health Services in Australia and Associations With Patterns of Ceftriaxone Consumption: A Retrospective Observational Study. J Infect Dis. 2026. PMID: 41967089. doi:10.1093/infdis/jiag192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。